(Reuters) - Allergan Plc on Tuesday reported a better-than-expected quarterly profit on strong demand for Botox, and said its migraine treatment met the main goals in a late-stage study.
![](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_tKvqKKkv16SmhUgg3Pd8x7CgA6zHbby-VuZDo9_6z_6Q1Ulb2P53KeiPDY9MgYmKdICFyApI10mndDH4Gn9zZPns0w1c3YauvIM8xr4PmcU00nc7yJBmWnvWdnj1PsEeRYxBEG8w=s0-d)
Allergan's profit beats; migraine drug succeeds in key study
Read More
Bagikan Berita Ini
0 Response to "Allergan's profit beats; migraine drug succeeds in key study"
Posting Komentar